Summit Therapeutics Share Discussion Threads

[football] 07/3/2018 18:03

more news soon

[football] 07/3/2018 17:57

what goes up?

[chrisatrdg] 07/3/2018 12:46

I agree with you HM & see this as a positive RNS & believe that Summit is moving itself towards an earlier submission to the FDA.

[waterloo01] 07/3/2018 12:09

Not sure what to make of today's RNS. Excellent for patients who'd been in phase 1, especially older boys who often have no other option. Not sure how many might be involved who aren't in any other trial, but numbers can't be huge.

Can see how it will add to total package but these results will be some time further down road.

[waterloo01] 06/3/2018 18:36

Absolutely agree. I listened to a few of the older boys talking about it from their perspective. Also how important even small changes make to their lives. One boy/man, says all he want's it to be able to maintain enough mobility to still play computer games, as they are the only thing that keeps him going as he declines.

[waterloo01] 06/3/2018 17:03

If anyone has a spare 6hrs.The Duchenne Patient-Focused Compass Meeting (Full Program)



Some rather real stories.

[chrisatrdg] 06/3/2018 17:01

Per Free-Money today from the other board:

'Hi Chris, You're right £100 is just a guess for Pharmaceutical selling the only drug in a $5bln+ market place with only 70million shares. Maybe £200 is more realistic :-)
As I said many more steps to becoming a pharmaceutical yet but look how far they've come in the last five/six years.
I'm still young enough and happy to wait a couple more years for the transformation and understand others will have difference agendas. Many will sell out on the way, rightly having achieved their goals.
They'll probably not only have 70million shares on a couple of years either. As Sarepta have found it's prudent to do placings on the way up to fill the bank account...maybe enough to buy Sarepta :-)'

[football] 06/3/2018 15:23

Is someone on the LSE message board saying £100 a share?

[chrisatrdg] 06/3/2018 14:33

PhaseOut DMD Interim Data



Summit website now updated with all related recents events to PhaseOut DMD.

[hugus maximus] 05/3/2018 16:45

Luminoso - that's a very good pro-Summit piece.

Sarepta looking very impressive today having just past their hightest share price so far ... currently above $71.

[luminoso] 05/3/2018 16:26

Seems the Summit connection is boosting SRPT's share price !

[football] 02/3/2018 23:44

12.28USD increase0.92 (8.10%)

[hugus maximus] 02/3/2018 09:58

Thanks Waterloo ... you just beat me to it. (Village here in Somerset cut off with all access blocked, so normal schedule a little hindered!)

At least summ mention of Summit! Wonder at what point Ingram's 'happiness' will turn to 'desire for acquisition'? (If it hasn't already?)

Good point about lack of enough boys in the 13% versus Summit's potential 100%.

EDIT - I also understood EU approval of eteplirsen was due end Feb? A negative announcement may well cause some trouble at mill and I've realised that there are many long term SRPT holders in the USA who, up until now, have been guarding their position very aggressively .. EU approval is crucial to maintain their status quo (IMHO)

[waterloo01] 02/3/2018 09:25

Chad Messer

Great. Thanks for taking my question and congrats on a strong near progress. Your partner Summit recently reported some Phase II data for their drug Ezutromid, I’m really interested in getting you guys thoughts on this early biomarker data particularly their ability to effect utrophin levels and some of the MRI findings that that they recorded?

Douglas Ingram

Summit our partner, we have ex-U.S. rights with Summit they have been a great partner with us in a number of regards and obviously we are very excited about their results, what they actually issued a released with further analysis on those results that was the 24 week results so we await to 48-week results as well and then we will see where we are from there, but we are very happy for them and we're happy for the results so for.

[waterloo01] 01/3/2018 23:27

SRPT disappoints on earnings. Finding it hard to find enough boys in the 13% it treats. Also some side effect issues.

At least it highlights the benefits of having a drug aimed at 100% of the population.

[chrisatrdg] 01/3/2018 22:42

Sarepta Therapeutics, Inc. (SRPT)FORM 10-K | Annual Report



Interesting read also includes about their view on what the FDA expect on progressing a drug & the stages they have to go through.

U.S. Drug Approval Process (Page 16)

[chrisatrdg] 01/3/2018 22:30

Extract from Sarepta SEC Schedule Y/E 31.12.2017

'Summit (Oxford) Ltd.

On October 3, 2016, we entered into the exclusive Collaboration and License Agreement (the “Collaboration Agreement”) with Summit which grants us the exclusive right to commercialize products in Summit’s utrophin modulator pipeline in the E.U., Switzerland, Norway, Iceland, Turkey and the Commonwealth of Independent States (the “Licensed Territory”).
Under the terms of the Collaboration Agreement, we made an up-front payment of $40.0 million to Summit, with the potential for additional payments of up to $192.0 million based on achievement of certain development and regulatory milestones for ezutromid. For each of Summit’s future generation small molecule utrophin modulators, we may be required to make up to $290.0 million in development and regulatory milestone payments. Additionally, on a product-by-product basis, we may be required to make up to $330.0 million in sales milestone payments.
The Collaboration Agreement also grants us an option to expand the Licensed Territory. If we exercise this option, then we will be liable for a one-time $10.0 million option fee as well as up to $7.0 million in regulatory milestone payments. For each of Summit’s lead product candidate, ezutromid, for the treatment of DMD, and its second generation and future generation small molecule utrophin modulators (collectively, the “Licensed Product”), we may be liable for up to $82.5 million in sales milestone payments.
Additionally, we may be required to make tiered royalty payments ranging from a low to high teens percentage of net sales on a product-by-product basis in the Licensed Territory.
Under the Collaboration Agreement, Summit was solely responsible for all research and development costs for the Licensed Products until December 31, 2017. Currently, Summit is responsible for 55.0% of the budgeted research and development costs related to the Licensed Products in the Licensed Territory, and we are be responsible for 45.0% of such costs. Any costs in excess of 110.0% of the budgeted amount will be borne by the party that incurred such costs. Summit is also obligated to spend a specified minimum amount on the research and development of certain Licensed Products prior to the end of 2019.

Manufacture and Supply of Licensed Products

Under the Collaboration Agreement, Summit has agreed to use commercially reasonable efforts to supply to us API, finished drug product and placebo so that we may conduct research, development and commercialization activities for the Licensed Products. We will also have the right to establish back up and second source suppliers under certain circumstances.

Commercialisation

Under the Collaboration Agreement, we will be solely responsible for all commercialization activities and associated costs relating to the Licensed Products in the Licensed Territory. We have agreed to use commercially reasonable efforts to commercialize the Licensed Products in specified countries within the Licensed Territory and, if the exclusive option to expand the Licensed Territory to include specified countries in South and Central America (the “Option Territory”) is exercised, to use commercially reasonable efforts to commercialize the Licensed Products in certain specified countries within the Option Territory.'

[chrisatrdg] 01/3/2018 21:40

Hi HM - I have just tuned in anything of interest relating to Summit.Regards Chris

Edit: In answer from one of the post presentation questions from the floor - 'Sarepta are happy with the recent results '- they seemed very positive with how their partner Summit is performing.

[hugus maximus] 01/3/2018 17:30

Be interesting to see if Summit is mentioned in Sarepta's 2017 Year End Conference call 4.30 EST (that's 9.30 pm this evening GMT ... I may listen tomorrow):

[waterloo01] 01/3/2018 17:26

SRPT call later. However this published study doesn't make good reading for their drug as in the early trial in didn't even get to 1% but got approved.



Thus, our study shows that presence of less than ~19% of the normal level of dystrophin protein is insufficient to normalize the NMJ deficits of mdx mice, but that ~50% of normal dystrophin level seems to be enough for normal synaptic function of the NMJ.

[waterloo01] 28/2/2018 19:19

Spoke too soon although good to see HC Wainwright up target to $20. They have obviously decided to move on from the $12 placing. From bulls to bears and back again?

[waterloo01] 27/2/2018 19:03

Well Nasdaq seems to have woken up a bit. $13.00